BiomX Inc./$PHGE
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About BiomX Inc.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Ticker
$PHGE
Sector
Primary listing
AMEX
Industry
Biotechnology
Headquarters
Ness Ziona, Israel
Employees
55
ISIN
US09090D3017
Website
BiomX Inc. Metrics
BasicAdvanced
$12M
-
-$2.13
1.44
-
Price and volume
Market cap
$12M
Beta
1.44
52-week high
$0.77
52-week low
$0.34
Average daily volume
225K
Financial strength
Current ratio
3.352
Quick ratio
3.059
Long term debt to equity
33.271
Total debt to equity
37.928
Profitability
EBITDA (TTM)
-35.453
Effective tax rate (TTM)
-0.11%
Management effectiveness
Return on assets (TTM)
-36.60%
Return on equity (TTM)
-34.02%
Valuation
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-0.208
Free cash flow yield (TTM)
-481.00%
Free cash flow per share (TTM)
-211.63%
Growth
Earnings per share change (TTM)
-66.31%
3-year earnings per share growth (CAGR)
-45.47%
BiomX Inc. News
AllArticlesVideos

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
GlobeNewsWire·2 months ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates
GlobeNewsWire·2 months ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BiomX Inc. stock?
BiomX Inc. (PHGE) has a market cap of $12M as of July 04, 2025.
What is the P/E ratio for BiomX Inc. stock?
The price to earnings (P/E) ratio for BiomX Inc. (PHGE) stock is 0 as of July 04, 2025.
Does BiomX Inc. stock pay dividends?
No, BiomX Inc. (PHGE) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next BiomX Inc. dividend payment date?
BiomX Inc. (PHGE) stock does not pay dividends to its shareholders.
What is the beta indicator for BiomX Inc.?
BiomX Inc. (PHGE) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.